Review





Similar Products

rat basophilic leukemia rbl 2h3 cells  (ATCC)
95
ATCC rat basophilic leukemia rbl 2h3 cells
Pluviatolide suppresses antigen-induced degranulation in mast cells without cytotoxicity. (A) Chemical structure of pluviatolide. (B) Cell viability of BMMCs after 24 h treatment with pluviatolide (n=5). (C) IC 50 value for β-hexosaminidase release inhibition in BMMCs. (D) β-hexosaminidase release from BMMCs stimulated for 15 min with 50 ng/mL DNP-HSA, with or without pluviatolide pretreatment. (E) β-hexosaminidase release from <t>RBL-2H3</t> cells stimulated for 15 min with 20 ng/mL DNP-HSA, with or without pluviatolide pretreatment. (F) BMMCs were pre-treated with 100 μM pluviatolide for 30 min, washed five times, and then stimulated with 50 ng/mL DNP-HSA for 15 min. Data are presented as mean ± SEM (n=5). * p <0.05; ** p <0.01; *** p <0.001; n.s., not significant vs. DNP-HSA only group. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test.
Rat Basophilic Leukemia Rbl 2h3 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rat basophilic leukemia rbl 2h3 cells/product/ATCC
Average 95 stars, based on 1 article reviews
rat basophilic leukemia rbl 2h3 cells - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
transit mrna transfection kit  (Mirus Bio)
99
Mirus Bio transit mrna transfection kit
Pluviatolide suppresses antigen-induced degranulation in mast cells without cytotoxicity. (A) Chemical structure of pluviatolide. (B) Cell viability of BMMCs after 24 h treatment with pluviatolide (n=5). (C) IC 50 value for β-hexosaminidase release inhibition in BMMCs. (D) β-hexosaminidase release from BMMCs stimulated for 15 min with 50 ng/mL DNP-HSA, with or without pluviatolide pretreatment. (E) β-hexosaminidase release from <t>RBL-2H3</t> cells stimulated for 15 min with 20 ng/mL DNP-HSA, with or without pluviatolide pretreatment. (F) BMMCs were pre-treated with 100 μM pluviatolide for 30 min, washed five times, and then stimulated with 50 ng/mL DNP-HSA for 15 min. Data are presented as mean ± SEM (n=5). * p <0.05; ** p <0.01; *** p <0.001; n.s., not significant vs. DNP-HSA only group. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test.
Transit Mrna Transfection Kit, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/transit mrna transfection kit/product/Mirus Bio
Average 99 stars, based on 1 article reviews
transit mrna transfection kit - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
transit mrna kit  (Mirus Bio)
99
Mirus Bio transit mrna kit
Pluviatolide suppresses antigen-induced degranulation in mast cells without cytotoxicity. (A) Chemical structure of pluviatolide. (B) Cell viability of BMMCs after 24 h treatment with pluviatolide (n=5). (C) IC 50 value for β-hexosaminidase release inhibition in BMMCs. (D) β-hexosaminidase release from BMMCs stimulated for 15 min with 50 ng/mL DNP-HSA, with or without pluviatolide pretreatment. (E) β-hexosaminidase release from <t>RBL-2H3</t> cells stimulated for 15 min with 20 ng/mL DNP-HSA, with or without pluviatolide pretreatment. (F) BMMCs were pre-treated with 100 μM pluviatolide for 30 min, washed five times, and then stimulated with 50 ng/mL DNP-HSA for 15 min. Data are presented as mean ± SEM (n=5). * p <0.05; ** p <0.01; *** p <0.001; n.s., not significant vs. DNP-HSA only group. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test.
Transit Mrna Kit, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/transit mrna kit/product/Mirus Bio
Average 99 stars, based on 1 article reviews
transit mrna kit - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
mirus mrna transfection kit  (Mirus Bio)
99
Mirus Bio mirus mrna transfection kit
Pluviatolide suppresses antigen-induced degranulation in mast cells without cytotoxicity. (A) Chemical structure of pluviatolide. (B) Cell viability of BMMCs after 24 h treatment with pluviatolide (n=5). (C) IC 50 value for β-hexosaminidase release inhibition in BMMCs. (D) β-hexosaminidase release from BMMCs stimulated for 15 min with 50 ng/mL DNP-HSA, with or without pluviatolide pretreatment. (E) β-hexosaminidase release from <t>RBL-2H3</t> cells stimulated for 15 min with 20 ng/mL DNP-HSA, with or without pluviatolide pretreatment. (F) BMMCs were pre-treated with 100 μM pluviatolide for 30 min, washed five times, and then stimulated with 50 ng/mL DNP-HSA for 15 min. Data are presented as mean ± SEM (n=5). * p <0.05; ** p <0.01; *** p <0.001; n.s., not significant vs. DNP-HSA only group. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test.
Mirus Mrna Transfection Kit, supplied by Mirus Bio, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mirus mrna transfection kit/product/Mirus Bio
Average 99 stars, based on 1 article reviews
mirus mrna transfection kit - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier

Image Search Results


Pluviatolide suppresses antigen-induced degranulation in mast cells without cytotoxicity. (A) Chemical structure of pluviatolide. (B) Cell viability of BMMCs after 24 h treatment with pluviatolide (n=5). (C) IC 50 value for β-hexosaminidase release inhibition in BMMCs. (D) β-hexosaminidase release from BMMCs stimulated for 15 min with 50 ng/mL DNP-HSA, with or without pluviatolide pretreatment. (E) β-hexosaminidase release from RBL-2H3 cells stimulated for 15 min with 20 ng/mL DNP-HSA, with or without pluviatolide pretreatment. (F) BMMCs were pre-treated with 100 μM pluviatolide for 30 min, washed five times, and then stimulated with 50 ng/mL DNP-HSA for 15 min. Data are presented as mean ± SEM (n=5). * p <0.05; ** p <0.01; *** p <0.001; n.s., not significant vs. DNP-HSA only group. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test.

Journal: Biomolecules & Therapeutics

Article Title: Pluviatolide Attenuates Type I Hypersensitivity through Regulation of Mast Cell Activation

doi: 10.4062/biomolther.2025.164

Figure Lengend Snippet: Pluviatolide suppresses antigen-induced degranulation in mast cells without cytotoxicity. (A) Chemical structure of pluviatolide. (B) Cell viability of BMMCs after 24 h treatment with pluviatolide (n=5). (C) IC 50 value for β-hexosaminidase release inhibition in BMMCs. (D) β-hexosaminidase release from BMMCs stimulated for 15 min with 50 ng/mL DNP-HSA, with or without pluviatolide pretreatment. (E) β-hexosaminidase release from RBL-2H3 cells stimulated for 15 min with 20 ng/mL DNP-HSA, with or without pluviatolide pretreatment. (F) BMMCs were pre-treated with 100 μM pluviatolide for 30 min, washed five times, and then stimulated with 50 ng/mL DNP-HSA for 15 min. Data are presented as mean ± SEM (n=5). * p <0.05; ** p <0.01; *** p <0.001; n.s., not significant vs. DNP-HSA only group. Statistical significance was determined using one-way ANOVA followed by Tukey’s post hoc test.

Article Snippet: Rat basophilic leukemia (RBL)-2H3 cells (ATCC, Manassas, VA, USA) were cultured in MEM supplemented with 15% FBS, 100 U/mL penicillin-streptomycin, and 4 mM L-glutamine in a 5% CO 2 humidified incubator at 37°C.

Techniques: Inhibition